Th1 and Th2 cells expressing HEL-specific TCR were prepared as
follows: Spleen and lymph node cells of 3A9 mice were pooled, and the
T-cell fraction was partially purified on enrichment columns (R&D
Systems, Minneapolis, MN), followed by purification of CD4 cells by a
magnetic sorting system (SuperMACS; Milteny Biotec, Sunnyvale, CA),
using beads directly coupled to anti-mouse CD4. Purified (>97%) CD4
cells were then cultured at 2.5 × 105/mL in
RPMI-1640 medium supplemented with 50 μM 2-mercaptoethanol (2-ME),
antibiotics, and 10% fetal bovine serum (complete medium) with 10×
irradiated syngeneic wild-type splenocytes, as antigen-presenting cells
(APCs), in the presence of 2 μg/mL HEL (Sigma, St Louis, MO), 10
ng/mL IL-12 (Sigma), and 10 μg/mL anti-IL-4 antibody (PharMingen, San
Diego, CA) for Th1 or 0.2 μg/mL HEL, 10 ng/mL IL-4, 10 μg/mL
anti-IFN-γ antibody, and 10 μg/mL anti-IL-12 antibody (all from
PharMingen) for Th2. After 3 days, cultured cells were expanded with 40
IU/mL IL-2 (Chiron Corp., Emeryville, CA) for 3 to 5 days and then
restimulated at 2.5 × 105/mL with 10×
irradiated syngeneic APCs in the presence of 2 μg/mL HEL, 40 IU/mL
IL-2, and 10 ng/mL IL-12 for Th1 or 0.2 μg/mL HEL, 40 IU/mL IL-2, and
10 ng/mL IL-4 for Th2. Three days later, cells were harvested, washed,
resuspended in RPMI-1640, and injected intravenously into recipient
mice, as indicated.